重大事件
即時報告
8-K
2026-07-22
碧迪高層人事變動 執行副總裁Garrison退休 BioPharma Systems改直屬CEO
AI 繁中摘要
📄 BD（Becton, Dickinson and Company）（NYSE: BDX）於2026年7月22日透過8-K申報公告，高層管理人事變動：執行副總裁兼Medical Essentials及BioPharma Systems總裁Michael（Mike）Garrison博士將於10月2日退休，結束超過20年的BD生涯👤。
Garrison在BD歷任多個要職，包括醫療業務總裁、用藥管理解決方案全球總裁及手術全球總裁，帶領團隊經歷多次轉型。CEO Tom Polen讚揚其以客戶、病人及員工為核心的領導風格，並感謝他對公司未來的佈局。退休生效前，Garrison將留任至財政年度末。BD已啟動全面搜尋，物色Medical Essentials下一任總裁；BioPharma Systems則改為直接向CEO匯報，反映該部門作為增長引擎的戰略重要性📈。
Garrison表示，能與優秀團隊共事推動全球醫療進步是莫大榮幸，並期待公司繼續引領護理創新。
此變動短期對營運影響有限，但BioPharma Systems直屬CEO的架構調整，或加強該業務的資源聚焦與執行效率，對投資者而言屬中性偏正面訊號。BD為全球純醫療科技龍頭，專注醫療必需品、互聯護理、生物製藥系統及介入治療，員工人數逾6萬，每年交付數十億產品。
展開英文正文
EX-99.1 2 bdnews_medessentialsbpsxpr.htm EX-99.1 Document NEWS RELEASE Mike Garrison to Retire from BD FRANKLIN LAKES, N.J. (July 22, 2026) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2. Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD’s Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery. Prior to joining BD in 2005, Garrison held various roles across R&D and marketing within the MedTech industry. "Mike has made a significant impact on BD over the past two decades, helping guide our company through periods of transformation while always keeping our customers, patients and associates at the center of his decisions," said Tom Polen, Chairman, CEO and President of BD. "He has built strong teams, developed exceptional leaders and helped position our business for the future. We are grateful for Mike's leadership, partnership and many contributions to BD, and we wish him well in his retirement." Garrison will remain in his role through the end of the fiscal year. A comprehensive search is underway to identify the next president of Medical Essentials. Going forward, BioPharma Systems will report directly to Polen, streamlining the operating model and reflecting the segment’s strategic importance as a growth driver. “It has been a privilege to spend more than two decades at BD, working alongside talented teams who are deeply committed to improving healthcare around the world,” Garrison said. “I will always value the people, purpose and impact that have made my time at BD so meaningful, and I look forward to seeing the company continue to advance the future of care.” # # # About BDBD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson. Contacts: Media Investors Megan DubrowskiSenior Director, Executive [email protected] Shawn Bevec SVP, Investor Relations [email protected]